COZADD BRUCE C 4

What Happened
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc, sold a total of 6,000 ordinary shares in open-market transactions on April 1, 2026. The sales were reported in three blocks: 3,684 shares at $190.22 for $700,778; 2,292 shares at $190.94 for $437,631; and 24 shares at $191.74 for $4,602. Total reported proceeds from these disposals were $1,143,011. These were sales (not purchases) and therefore represent liquidity by the insider rather than an additional investment.

Key Details

• Transaction date: April 1, 2026 (filed April 3, 2026 — appears timely under the two-business-day rule).
• Trade details: 3,684 sh @ $190.22 ($700,778); 2,292 sh @ $190.94 ($437,631); 24 sh @ $191.74 ($4,602).
• Total shares sold: 6,000; total proceeds: $1,143,011.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Notable footnotes:
  • The sales were made pursuant to a Rule 10b5‑1 plan adopted Nov 26, 2025; transactions occurred automatically and were nondiscretionary.
  • Some reported prices reflect weighted-average prices across multiple executions; the reporting person offers to provide full transaction-level details on request.
• Filing timeliness: Filing date (Apr 3, 2026) appears timely for an Apr 1, 2026 transaction.

Context
Sales executed under a pre-arranged 10b5‑1 plan are common for insiders managing routine equity liquidity and are carried out automatically regardless of short-term company developments. This filing documents the disposition and associated proceeds but does not by itself indicate the insider’s view of the company’s long-term prospects.